<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00939757</url>
  </required_header>
  <id_info>
    <org_study_id>178-CL-041</org_study_id>
    <nct_id>NCT00939757</nct_id>
  </id_info>
  <brief_title>Study of the Effect of Food on the Pharmacokinetics of Mirabegron</brief_title>
  <official_title>A Phase 1, Open-Label, Randomized, Single Oral Dose, Three-Way Crossover Study to Assess the Effect of Food on the Pharmacokinetics of Mirabegron</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of food on the pharmacokinetics of a single
      oral dose of mirabegron in healthy male and female subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be assigned in a random order to receive 3 dosing regimens:

        1. a single oral dose under a fasting condition;

        2. a single oral dose with food (low fat breakfast);

        3. a single oral dose with food (high fat breakfast).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the effects of food on the pharmacokinetics of a single oral dose of mirabegron</measure>
    <time_frame>4-5 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Healthy</condition>
  <condition>Pharmacokinetics of Mirabegron</condition>
  <arm_group>
    <arm_group_label>1. mirabegron, lower dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2. mirabegron, higher dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mirabegron</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>1. mirabegron, lower dose</arm_group_label>
    <arm_group_label>2. mirabegron, higher dose</arm_group_label>
    <other_name>YM178</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject must weigh at least 45 kg and have a body mass index (BMI) between 20.0
             and 32.0 kg/m2 , inclusive

          -  The subject must have a normal or clinically non-significant 12 lead ECG as well as
             normal or clinically non-significant laboratory test results

          -  Female subjects must be post-menopausal (defined as at least 2 years without menses),
             surgically sterile, or practicing effective contraception, and will continue to use
             effective contraception during the study period. All females must be non-lactating,
             and must have a negative pregnancy test result

          -  The subject must have negative test results for drugs of abuse and alcohol screens

          -  The subject must have good venous access in both arms

        Exclusion Criteria:

          -  The subject has evidence of QTc interval &gt;430 msec for male, &gt;450 msec for female

          -  The subject has liver function test values (ALT, AST, or bilirubin) above the upper
             limit of normal

          -  The subject has a history or presence of psychiatric illness, serious active or
             recurrent infection, or any medical condition or disorder that precludes the subject
             from participating in the study

          -  The subject has a previous history of cancer other than basal cell carcinoma or Stage
             1 squamous cell carcinoma that has not been in remission for at least 5 years

          -  The subject has donated or lost â‰¥ 450 mL blood within 56 days prior to study drug
             administration or has donated plasma within 7 days prior to study drug administration

          -  The subject has received or is anticipated to receive a prescription drug within 14
             days prior to Day -1 of Period 1 (within 30 days 1 for any long acting treatments such
             as depot formulations). Subject has taken any over-the-counter (OTC) medications,
             including complementary and alternative medicines (except for oral contraceptives and
             occasional use of acetaminophen of up to 2000 mg/day but not more than 4 days per
             week) within 14 days

          -  The subject has consumed alcohol, xanthine derivative-containing food/beverages (tea,
             chocolate), grapefruit juice, grapefruit-containing products or Seville oranges (e.g.,
             bitter marmalade) within 48 hours before admission into the unit

          -  The subject has used tobacco-containing products and nicotine-containing products
             within 6 months

          -  The subject consumes more than 5 units of alcoholic beverages (one unit is 12 ounces
             of beer, 4 ounces of wine or 1 ounce of spirits) per week, or has a history of
             substance abuse, drug addiction, or alcoholism within past 2 years

          -  The subject is known to have hepatitis or HIV-1 and/or HIV-2, or is positive for
             hepatitis A antibody IgM, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV)
             antibody
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrDetail_e.jsp?resultId=632</url>
    <description>Link to Results on JAPIC</description>
  </link>
  <reference>
    <citation>Lee J, Zhang W, Moy S, Kowalski D, Kerbusch V, van Gelderen M, Sawamoto T, Grunenberg N, Keirns J. Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults. Clin Ther. 2013 Mar;35(3):333-41. doi: 10.1016/j.clinthera.2013.02.014.</citation>
    <PMID>23497763</PMID>
  </reference>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2009</study_first_submitted>
  <study_first_submitted_qc>July 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2009</study_first_posted>
  <last_update_submitted>June 24, 2013</last_update_submitted>
  <last_update_submitted_qc>June 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteer subjects</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>YM178</keyword>
  <keyword>mirabegron</keyword>
  <keyword>food</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mirabegron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

